Isaac Brownell, M.D., Ph.D.

Summary

Isaac Brownell, M.D., Ph.D., is a board-certified dermatologist specializing in cutaneous oncology and oncodermatology. He directs a research program encompassing basic, translational, and clinical investigations of skin homeostasis and skin cancer. Dr. Brownell is an attending physician on the NIH Clinical Center’s Dermatology Consultation Service and he co-directs the Cutaneous Oncology Program at the Murtha Cancer Center, Walter Reed National Military Medical Center. He is also an Adjunct Investigator at the National Cancer Institute’s Center for Immuno-Oncology.

Research Statement

Dr. Brownell studies the regulation of cutaneous stem cells and the molecular pathogenesis of skin cancer. A major research focus is the biology of neuroendocrine Merkel cells and the oncogenesis of Merkel cell carcinoma. Using mouse genetics, his laboratory investigates the signaling pathways that regulate skin stem cell development and maintenance. His research also uses preclinical models to study therapeutic targets identified using oncogenomic analyses of human skin tumors, high-throughput drug screening, and functional genomic screens. Leveraging data from clinical registries and databases, Dr. Brownell investigates the biology and management of high-risk skin cancers. In collaboration with National Cancer Institute oncologists, Dr. Brownell conducts early-phase clinical trials and studies the dermatologic complications of cancer and cancer therapy.

Scientific Publications

Interlocking host and viral cis-regulatory networks drive Merkel cell carcinoma.

Miao L, Milewski D, Coxon A, Gelb T, Garman KA, Porch J, Khanna A, Collado L, Hill NT, Daily K, Vilasi S, Reed D, Alexander T, Starrett GJ, Chakraborty M, Song Y, Choi R, Gangalapudi V, Seaman J, Morton A, Busam KJ, Vakoc CR, Urban DJ, Shen M, Hall MD, Sallari R, Khan J, Gryder BE, Brownell I
J Clin Invest.
2025 Dec 15;
135(24).
doi: 10.1172/JCI188924
PMID: 41392987

High-throughput screening identifies Aurora kinase B as a critical therapeutic target for Merkel cell carcinoma.

Gelb T, Garman KA, Urban D, Coxon A, Gryder B, Hill NT, Miao L, Lee T, Lee O, Chakka S, Braisted J, Jarvis JE, Glavin R, Raj TS, Xiao Y, Difilippantonio S, Wang AQ, Shen M, Cheng KC, Lal-Nag M, Hall MD, Brownell I
Nat Commun.
2025 Feb 12;
16(1).
doi: 10.1038/s41467-025-56504-7
PMID: 39939315

Single cell analysis of developing Merkel cells reveals the emergence of non-coding RNA biotypes as a hallmark of terminal differentiation.

Miao L, Collado L, Barkdull S, Hallaert P, Martin MR, Gryder BE, Kelly MC, Dell'Orso S, Kelley MW, Brownell I
Cell Death Differ.
2026 Jul;
33(7).
doi: 10.1038/s41418-026-01663-3
PMID: 41634368

A Cascade of Wnt, Eda, and Shh Signaling Is Essential for Touch Dome Merkel Cell Development.

Xiao Y, Thoresen DT, Miao L, Williams JS, Wang C, Atit RP, Wong SY, Brownell I
PLoS Genet.
2016 Jul;
12(7).
doi: 10.1371/journal.pgen.1006150
PMID: 27414798

Neural Hedgehog signaling maintains stem cell renewal in the sensory touch dome epithelium.

Xiao Y, Thoresen DT, Williams JS, Wang C, Perna J, Petrova R, Brownell I
Proc Natl Acad Sci U S A.
2015 Jun 9;
112(23).
doi: 10.1073/pnas.1504177112
PMID: 26015562

The biology and treatment of Merkel cell carcinoma: current understanding and research priorities.

Harms PW, Harms KL, Moore PS, DeCaprio JA, Nghiem P, Wong MKK, Brownell I, International Workshop on Merkel Cell Carcinoma Research (IWMCC) Working Group
Nat Rev Clin Oncol.
2018 Dec;
15(12).
doi: 10.1038/s41571-018-0103-2
PMID: 30287935

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P
Lancet Oncol.
2016 Oct;
17(10).
doi: 10.1016/S1470-2045(16)30364-3
PMID: 27592805

Genetic Risk Factors for Early-Onset Merkel Cell Carcinoma.

Mohsin N, Hunt D, Yan J, Jabbour AJ, Nghiem P, Choi J, Zhang Y, Freeman AF, Bergerson JRE, Dell'Orso S, Lachance K, Kulikauskas R, Collado L, Cao W, Lack J, Similuk M, Seifert BA, Ghosh R, Walkiewicz MA, Brownell I
JAMA Dermatol.
2024 Feb 1;
160(2).
doi: 10.1001/jamadermatol.2023.5362
PMID: 38170500

Population differences in Merkel cell carcinoma by virus status and anatomic site: A multi-cohort analysis including institutional, SEER, and NCDB data.

Martin MR, Vilasi SM, Saito Y, Mohsin N, Jarvis JE, Hallaert P, Reed DJ, Miao L, Tribble JT, Cahoon EK, Pfeiffer RM, Lachance K, Kulikauskas R, Nghiem P, Brownell I
J Am Acad Dermatol.
2026 Mar;
94(3).
doi: 10.1016/j.jaad.2025.11.023
PMID: 41242630

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer.

Silk AW, Barker CA, Bhatia S, Bollin KB, Chandra S, Eroglu Z, Gastman BR, Kendra KL, Kluger H, Lipson EJ, Madden K, Miller DM, Nghiem P, Pavlick AC, Puzanov I, Rabinowits G, Ruiz ES, Sondak VK, Tavss EA, Tetzlaff MT, Brownell I
J Immunother Cancer.
2022 Jul;
10(7).
doi: 10.1136/jitc-2021-004434
PMID: 35902131

Education

Baylor College of Medicine, Houston, TX
M.D./Ph.D.

University of Maryland, College Park
B.S., Electrical Engineering and B.S., Mathematics

Experience

After graduating from the Medical Scientist Training Program at Baylor College of Medicine, Dr. Brownell completed an internship at Christus St. Joseph Hospital in Houston, TX, and a Dermatology residency at the New York University School of Medicine. He completed a postdoctoral research fellowship on Hedgehog signaling and cutaneous stem cells in the lab of Dr. Alexandra Joyner at Memorial Sloan-Kettering Cancer Center where he was also a clinical faculty member on the Dermatology Service. His clinical practice focused on patients with high-risk skin cancers.

In 2011, Dr. Brownell joined the Dermatology Branch in the Center for Cancer Research, National Cancer Institute (NCI). In 2017, he and the Dermatology Branch moved to the National Institute of Arthritis and Musculoskeletal and Skin Diseases. He is currently a Senior Investigator, Co-leader of the Dermatology Branch, and Head of the Cutaneous Development and Carcinogenesis Section. Dr. Brownell also holds an Adjunct Investigator appointment in the NCI’s Center for Immuno-Oncology and is an Adjunct Assistant Professor of Dermatology at the Uniformed Services University of the Health Sciences. He co-directs the Cutaneous Oncology Program at the Murtha Cancer Center, Walter Reed National Military Medical Center.

Last Updated: